EA
LXRX icon

Emerald Acquisition’s Lexicon Pharmaceuticals LXRX Stock Holding History

Emerald Acquisition’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.66M Sell
92,112
-150,344
-62% -$2.42M ﹤0.01% 1847
2016
Q2 		$3.48M Buy
+242,456
New +$3.29M 0.01% 1555

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's LXRX Position: Q3 2016 in Review

Emerald Acquisition reduced its Lexicon Pharmaceuticals (LXRX) stake by 62% in Q3 2016, selling an estimated $2.42M and leaving 92,112 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1847.

Emerald Acquisition first reported a position in LXRX in Q2 2016 and has held it in 2 quarters since. The position peaked at $3.48M in Q2 2016. 142 funds tracked by Wall St. Rank hold LXRX as of Q3 2016.

  • Emerald Acquisition held 92,112 shares of Lexicon Pharmaceuticals worth $1.66M as of Q3 2016.
  • Emerald Acquisition sold 150,344 Lexicon Pharmaceuticals shares in Q3 2016, an estimated $2.42M.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1847 holding.
  • Emerald Acquisition first reported a position in Lexicon Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Lexicon Pharmaceuticals position peaked at $3.48M in Q2 2016.
  • 142 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.